Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Aniracetam vs Bacopa Monnieri: Bacopa Monnieri has the stronger overall evidence (6 vs 4/10); they're alternatives for improve memory & learning — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Bacopa Monnieri wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Aniracetam and Bacopa Monnieri have evidence — compare verdict strength side-by-side.
400 mg daily, the dose the cited trials support (they used a single 400 mg dose, or 400 to 600 mg a day where aniracetam was the comparison drug). Label products suggest 750-1,500 mg a day in divided doses, a dose no cited trial used.
With fat-containing food (improves absorption), Divided into 2-3 doses due to short half-life
Aniracetam powder or capsules
300-450mg daily (standardized to 50% bacosides)
With fatty meal for absorption
Bacognize® or Synapsa® standardized extract
1-2 weeks
30-60 minutes
1-2 hours
Per dose
8-12 weeks
8-12 weeks
First 2 weeks
First week
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study
CNS neuroscience & therapeutics (2012) · Observational · n=276
In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months.
[Clinical study on a randomized, double-blind control of Shenwu gelatin capsule in treatment of mild cognitive impairment]
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007) · Rct · n=166
Double-blind randomised trial in 166 people with mild cognitive impairment, in which aniracetam was the active comparator for the Chinese herbal Shenwu capsule, each taken three times a day for 3 months.
Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review
Nutrients (2025) · Systematic review
The evidence revealed the potential use of supplements as complementary ADHD treatments under clinical guidance.
Effectiveness of Bacopa Monnieri (Brahmi) in the management of schizophrenia: a systematic review
Nutritional neuroscience (2025) · Systematic review
Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population.
Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability
Nutrients (2025) · Review
Animal studies have shown promising results in reducing symptoms and protecting against neurodegeneration.
The 300 mg point rests on four 12-week placebo-controlled trials of standardised extracts at 300 mg a day. Three found better verbal learning or delayed recall than placebo (PMID 11498727, 20590480 with 98 older adults, 18611150 with 54 adults over 65). The largest, 101 adults with memory complaints (PMID 41091332), found no difference in verbal learning, attention or working memory. The 160 mg point is one 2-month trial in 62 people with mild cognitive impairment (PMID 38538390): attention improved, and the overall cognitive score differed from placebo only at the final visit. No trial compared doses within one study, and none gave more than 300 mg a day for weeks, so no optimal dose or safety ceiling can be read from them. Two trials reported more gastrointestinal complaints on bacopa.
AI-estimated from published studies. Interpret as directional guidance.
Bacopa Monnieri has a higher evidence score (6/10 vs 4/10) and wins in 2 of 3 categories.
For improve memory & learning, Bacopa Monnieri has a higher relevance score (95 vs 20).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.